Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lexaria Bioscience Corp

1.32
-0.1200-8.33%
Post-market: 1.320.00000.00%19:11 EDT
Volume:26.73K
Turnover:36.61K
Market Cap:23.17M
PE:-2.58
High:1.41
Open:1.35
Low:1.32
Close:1.44
Loading ...

Lexaria Bioscience Receives Ethics Board Approval for Oral Liraglutide Pilot Study

MT Newswires Live
·
15 Jan

Lexaria’s human GLP-1 study 5 receives IRB approval

TIPRANKS
·
15 Jan

Lexaria Bioscience Corp: Co's Human Glp-1 Study #5 Receives Independent Review Board Approval

THOMSON REUTERS
·
15 Jan

Lexaria’s Human GLP-1 Study #5 Receives Independent Review Board Approval

ACCESSWIRE
·
15 Jan

Lexaria Bioscience Says Oral DehydraTECH-Tirzepatide Causes Fewer Adverse Effects

MT Newswires Live
·
14 Jan

Lexaria Bioscience announces partial results from GLP-1-H24-3 study

TIPRANKS
·
14 Jan

Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)

ACCESSWIRE
·
14 Jan

Lexaria Bioscience First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.
·
14 Jan

Lexaria Bioscience Corp reports results for the quarter ended November 30 - Earnings Summary

Reuters
·
11 Jan

Lexaria Bioscience Corp expected to post a loss of 12 cents a share - Earnings Preview

Reuters
·
09 Jan

Lexaria Bioscience’s Phase 1b study starts patient dosing, says H.C. Wainwright

TIPRANKS
·
21 Dec 2024

Lexaria Bioscience Initiates Promising Drug Study

TIPRANKS
·
20 Dec 2024

Lexaria Bioscience begins dosing for GLP-1 study #4

TIPRANKS
·
19 Dec 2024

Lexaria's Registered GLP-1 Study #4 Begins Dosing

ACCESSWIRE
·
19 Dec 2024

BRIEF-Lexaria Bioscience Says Unit Finalizes Project Agreement With Novotech

Reuters
·
19 Dec 2024

Lexaria Bioscience Corp - Unit Finalizes Project Agreement With Novotech

THOMSON REUTERS
·
19 Dec 2024